LYON, FRANCE (May 27, 2020) – Signia Therapeutics announced today that it has received a grant of € 2.38 millionfrom the European Commission as part of the “EIC Accelerator Phase 2” (SME Instrument) call for projects for the development of its SIGNATURA®platform dedicated to the repositioning of drugs. The SIGNATURA® platform has already enabled … Continue reading SIGNIA THERAPEUTICS obtains EUROPEAN FUNDING in recognition of its major achievements and to ACCELERATE THE DEVELOPMENT OF ITS SIGNATURA® PLATFORM